Reading this review on immunotherapy in glioblastoma (nature.com/articles/s4157…) @NatRevClinOncol . A few odds and ends make me wonder - is there going to be a special role for NK cells in glioblastoma? Should we be aiming to target them for more effective therapies?
Checkpoint blockade hasn’t shown much efficacy in glioblastoma, in line with relatively low mutational burden (nejm.org/doi/full/10.10…) @NEJM. Also in line with the brain as “immunoprivileged”, or at least as a place with "unusual" immune activity.
First started thinking about NK cells in GBM after reading excellent study on PDGF-DD as an activating NK cell ligand (sciencedirect.com/science/articl…) @CellCellPress - striking human data from GBM cohorts, especially with greater infiltration of NK cells than T cells into tumor.
Oncolytic virotherapy can, in addition to direct killing of tumor cells, also increase immune responses - and if glioblastoma is really a poorly T-cell infiltrated tumor, then NK cells provide a good anti-viral response to further kill infected cells.
And NK cells can definitely get in and kill oncolytic-virus-infected glioblastoma cells - nature.com/articles/nm.30…@NatureMedicine. In that case, they were actually too efficient and limited therapy efficacy by killing so quickly that the virus couldn’t spread.
(Aside: it’s interesting that CD155, the poliovirus receptor, is a ligand for DNAM1/TIGIT. And while *neurovirulence* of poliovirus seems to be driven by IRES, *neurotropism* isn’t… Does internalization of CD155 by poliovirus internalization matter for NK cell function?)
But things get weirder, suggesting more roles for NK cells than I naively expected - a DC vaccine in glioblastoma is inducing an NK cell response that’s more important for survival than CD8+ T cells? tandfonline.com/doi/full/10.10…
And, in line with interesting things happening in the brain immunologically, NK cells could be doing wildly different things - and there’s plenty of evidence around that they may actually be taking on anti-inflammatory roles in the brain.
So, while there’s a lot of uncertainty and some conflicting evidence (in my light reading alone!), I think the weight is leaning towards the idea that we should be taking a closer look at NK cells in glioblastoma, especially as targets for new immunotherapies.
Are they killing APCs and T cells (as in MS/EAE)? Are they helpful or hurting in oncolytic virotherapy (in humans specifically)? The impairment of oHSV virotherapy was mediated by NK-receptor ligands upregulated by the virus - maybe that's not the case in zika / poliovirus?
I didn't find a definitive answer on the rate on MHC Class I loss in GBM, which would be good to know. And a little more definitive answer on infiltration, and the exact phenotype of whatever NK cells are in the tumor, would be good to see as well.
There’s some other biology that, as an armchair fan of NK cells (at best) and even less knowledgable about neuroimmunology, I’m sure I’m missing. Didn’t even get to skim plenty of other interesting NK-in-the-brain stories, like this one ncbi.nlm.nih.gov/pubmed/28314594.
But at a high level, it looks like there are lots of opportunities for new science, a deeper understanding of NK cells in the brain, and perhaps better outcomes for a still-horrifying disease. #Glioblastoma#Immunotherapy#NaturalKillerCells
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Here’s a thread on anti-interferon autoantibodies, viral infections, and human immunology. This is less a covid thread, and more an anti-covid thread, if anything…
Summary: anti-IFN auto-Abs may be reflective of chronic inflammation, and may pre-exist in vulnerable groups at high levels. Presence in severe covid cases may therefore reflect basal immune variation which impacts covid, rather than a special covid-specific phenomenon.
This is prompted based on the new Science paper on autoantibodies against Type I IFNs in severe covid patients (science.sciencemag.org/content/early/…). Basically, ~10% of severe covid patients had high titer anti-IFNa antibodies that were functionally neutralizing.
I'm grateful that others have put together resources like bit.ly/ANTIRACISMRESO…, which has helped me learn to be better. So You Want To Talk About Race by @IjeomaOluo and How To Be An Antiracist by @DrIbram have been amazing, and I'm looking forward to reading deeper.
I haven't seen a similar central resource for donations, but various recommendations led me to eji.org (Equal Justice initiative, focused on criminal justice reform and education), voterparticipation.org (get people registered to vote)...
The original paper, which was mainly based on the temperature-dependent fluorescence of a mitochondria-targeting probe, was accompanied by a “Primer” (journals.plos.org/plosbiology/ar…) highlighting potential flaws and implications, a special sort-of-peer-review step by PLOS Biology.
This new awesome resource @naturemethods - nature.com/articles/s4159… - offers some intriguing orthogonal validation. This is a proteome-wide study of protein thermal stability across 13 organisms, conducted using a mass-spec-based approach.
Super neat story on how cellular quality control impacts the mutational landscape of proteins - beneficial mutations in DHFR during deep mutational scanning are totally altered dependent on cellular QC #Biophysics#Evolutionbiorxiv.org/content/10.110… Way to go! @KortemmeLab
In an initial DMS experiment on DHFR, there were a large number (25% of all sequences!) of advantageous mutations spread across the whole protein. Reintroduction of QC protein Lon reduced the number of advantageous mutants and lowered average benefit of those mutations
Changes in selection coefficient (the “advantageous-ness”) were most striking at hydrophobic/aromatic residues and buried residues - and these correlate with Tm changes of variants. So Lon seems to be imposing higher standards on DHFR, particularly for destabilizing core mutants
A couple interesting bits of preliminary data on Langerhans cells and the huLangerin mouse used to study them. Effects of developmental absence of LCs on keratinocytes and T cells, and huLangerin-YFP labels some neurons (check your Cre mice!) #Genetics#Immunology
First - effect of loss of LCs in the huLangerin-DTA mice - biorxiv.org/content/10.110…. Bulk RNA-seq showed changes in keratinocytes and dendritic epidermal T cells, including cell-type specific changes (e.g. loss of IL17 pathway in DETCs).
Unfortunately, underlying data (either gene expression tables or raw RNA-seq data) don’t currently seem available, but hopefully the authors get that up shortly. Will be interesting to look at and prompt some hypotheses about how LCs control homeostasis and development.
CYTOF analysis of human neutrophils - 7 populations with differing phagocytosis, ROS, and FACS-compatible surface marker phenotypes. Changes in distribution between healthy + melanoma patients. #Immunology#Cancer#Neutrophilsbiorxiv.org/content/10.110…
Circulating neutrophil precursors, aged neutrophils, and a few populations of mature and immature neutrophils. Melanoma stage correlates with loss of dominant N2 (mature, ROS++, lowly phagocytic), and increase of N5 (immature, non-proliferative, ROS+, lowly phagocytic).
Interesting to note the phagocytosis-SSC staining in Fig4A - big changes in SSC for some populations with zymosan, others not so much - degranulation, different phagosomes…? Similarly, bimodal peaks for ROS production in same populations…